Annual Accounts Payable
$14.39 M
+$3.99 M+38.42%
31 December 2023
Summary:
Lexicon Pharmaceuticals annual accounts payable is currently $14.39 million, with the most recent change of +$3.99 million (+38.42%) on 31 December 2023. During the last 3 years, it has risen by +$8.92 million (+163.10%). LXRX annual accounts payable is now -72.79% below its all-time high of $52.88 million, reached on 31 December 2016.LXRX Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Payable
$14.20 M
+$1.98 M+16.21%
30 September 2024
Summary:
Lexicon Pharmaceuticals quarterly accounts payable is currently $14.20 million, with the most recent change of +$1.98 million (+16.21%) on 30 September 2024. Over the past year, it has increased by +$2.17 million (+17.99%). LXRX quarterly accounts payable is now -78.66% below its all-time high of $66.55 million, reached on 31 March 2018.LXRX Quarterly Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
LXRX Accounts Payable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +38.4% | +18.0% |
| 3 y3 years | +163.1% | +70.2% |
| 5 y5 years | +19.4% | -32.1% |
LXRX Accounts Payable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +163.1% | -1.3% | +93.3% |
| 5 y | 5 years | at high | +163.1% | -52.3% | +188.3% |
| alltime | all time | -72.8% | +1107.1% | -78.7% | +752.0% |
Lexicon Pharmaceuticals Accounts Payable History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $14.20 M(+16.2%) |
| June 2024 | - | $12.22 M(+51.5%) |
| Mar 2024 | - | $8.07 M(-43.9%) |
| Dec 2023 | $14.39 M(+38.4%) | $14.39 M(+19.5%) |
| Sept 2023 | - | $12.04 M(+14.6%) |
| June 2023 | - | $10.50 M(+1.8%) |
| Mar 2023 | - | $10.31 M(-0.8%) |
| Dec 2022 | $10.39 M(+13.6%) | $10.39 M(+10.3%) |
| Sept 2022 | - | $9.43 M(+28.3%) |
| June 2022 | - | $7.35 M(-21.2%) |
| Mar 2022 | - | $9.32 M(+1.8%) |
| Dec 2021 | $9.15 M(+67.3%) | $9.15 M(+9.7%) |
| Sept 2021 | - | $8.35 M(-2.3%) |
| June 2021 | - | $8.54 M(+73.5%) |
| Mar 2021 | - | $4.93 M(-9.9%) |
| Dec 2020 | $5.47 M(-55.1%) | $5.47 M(-53.4%) |
| Sept 2020 | - | $11.73 M(-60.6%) |
| June 2020 | - | $29.76 M(+63.2%) |
| Mar 2020 | - | $18.24 M(+49.7%) |
| Dec 2019 | $12.18 M(+1.0%) | $12.18 M(-41.8%) |
| Sept 2019 | - | $20.91 M(+108.5%) |
| June 2019 | - | $10.03 M(-27.7%) |
| Mar 2019 | - | $13.87 M(+15.1%) |
| Dec 2018 | $12.05 M(-68.9%) | $12.05 M(-76.6%) |
| Sept 2018 | - | $51.48 M(+2.0%) |
| June 2018 | - | $50.45 M(-24.2%) |
| Mar 2018 | - | $66.55 M(+71.7%) |
| Dec 2017 | $38.76 M(-26.7%) | $38.76 M(-26.3%) |
| Sept 2017 | - | $52.63 M(+20.0%) |
| June 2017 | - | $43.86 M(+4.6%) |
| Mar 2017 | - | $41.95 M(-20.7%) |
| Dec 2016 | $52.88 M(+168.1%) | $52.88 M(+27.3%) |
| Sept 2016 | - | $41.55 M(+47.2%) |
| June 2016 | - | $28.23 M(+10.5%) |
| Mar 2016 | - | $25.54 M(+29.5%) |
| Dec 2015 | $19.73 M(+51.0%) | $19.73 M(+20.6%) |
| Sept 2015 | - | $16.36 M(+44.8%) |
| June 2015 | - | $11.29 M(-7.0%) |
| Mar 2015 | - | $12.14 M(-7.1%) |
| Dec 2014 | $13.06 M(+34.5%) | $13.06 M(+34.1%) |
| Sept 2014 | - | $9.74 M(+16.7%) |
| June 2014 | - | $8.35 M(+18.1%) |
| Mar 2014 | - | $7.07 M(-27.2%) |
| Dec 2013 | $9.71 M(+26.8%) | $9.71 M(+0.1%) |
| Sept 2013 | - | $9.71 M(+54.6%) |
| June 2013 | - | $6.28 M(+15.4%) |
| Mar 2013 | - | $5.44 M(-29.0%) |
| Dec 2012 | $7.66 M | $7.66 M(+77.9%) |
| Sept 2012 | - | $4.31 M(-6.0%) |
| June 2012 | - | $4.58 M(-14.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2012 | - | $5.32 M(-11.9%) |
| Dec 2011 | $6.04 M(+91.3%) | $6.04 M(+9.3%) |
| Sept 2011 | - | $5.53 M(+50.5%) |
| June 2011 | - | $3.67 M(-32.7%) |
| Mar 2011 | - | $5.45 M(+72.6%) |
| Dec 2010 | $3.16 M(-46.6%) | $3.16 M(-11.0%) |
| Sept 2010 | - | $3.55 M(+0.1%) |
| June 2010 | - | $3.55 M(-25.7%) |
| Mar 2010 | - | $4.77 M(-19.4%) |
| Dec 2009 | $5.92 M(-25.3%) | $5.92 M(+73.4%) |
| Sept 2009 | - | $3.41 M(+6.3%) |
| June 2009 | - | $3.21 M(+4.1%) |
| Mar 2009 | - | $3.08 M(-61.1%) |
| Dec 2008 | $7.93 M(+7.9%) | $7.93 M(-1.6%) |
| Sept 2008 | - | $8.05 M(+1.7%) |
| June 2008 | - | $7.92 M(+86.3%) |
| Mar 2008 | - | $4.25 M(-42.1%) |
| Dec 2007 | $7.34 M(+12.8%) | $7.34 M(+49.5%) |
| Sept 2007 | - | $4.91 M(+4.5%) |
| June 2007 | - | $4.70 M(+7.7%) |
| Mar 2007 | - | $4.37 M(-33.0%) |
| Dec 2006 | $6.51 M(-5.4%) | $6.51 M(+52.6%) |
| Sept 2006 | - | $4.27 M(-1.3%) |
| June 2006 | - | $4.33 M(+20.5%) |
| Mar 2006 | - | $3.59 M(-47.9%) |
| Dec 2005 | $6.88 M(-9.1%) | $6.88 M(+83.5%) |
| Sept 2005 | - | $3.75 M(+33.9%) |
| June 2005 | - | $2.80 M(-19.8%) |
| Mar 2005 | - | $3.50 M(-53.9%) |
| Dec 2004 | $7.57 M(+28.7%) | $7.57 M(+92.8%) |
| Sept 2004 | - | $3.93 M(+5.1%) |
| June 2004 | - | $3.74 M(-2.1%) |
| Mar 2004 | - | $3.82 M(-35.1%) |
| Dec 2003 | $5.88 M(+34.4%) | $5.88 M(+48.6%) |
| Sept 2003 | - | $3.96 M(-2.9%) |
| June 2003 | - | $4.08 M(+48.2%) |
| Mar 2003 | - | $2.75 M(-37.1%) |
| Dec 2002 | $4.38 M(+38.2%) | $4.38 M(+2.5%) |
| Sept 2002 | - | $4.27 M(-3.1%) |
| June 2002 | - | $4.41 M(+8.9%) |
| Mar 2002 | - | $4.05 M(+27.7%) |
| Dec 2001 | $3.17 M(+25.6%) | $3.17 M(-23.2%) |
| Sept 2001 | - | $4.13 M(-36.1%) |
| June 2001 | - | $6.46 M(+105.9%) |
| Mar 2001 | - | $3.14 M(+24.3%) |
| Dec 2000 | $2.52 M(+111.7%) | $2.52 M(+8.4%) |
| Sept 2000 | - | $2.33 M(+39.7%) |
| June 2000 | - | $1.67 M(-15.4%) |
| Mar 2000 | - | $1.97 M |
| Dec 1999 | $1.19 M | - |
FAQ
- What is Lexicon Pharmaceuticals annual accounts payable?
- What is the all time high annual accounts payable for Lexicon Pharmaceuticals?
- What is Lexicon Pharmaceuticals annual accounts payable year-on-year change?
- What is Lexicon Pharmaceuticals quarterly accounts payable?
- What is the all time high quarterly accounts payable for Lexicon Pharmaceuticals?
- What is Lexicon Pharmaceuticals quarterly accounts payable year-on-year change?
What is Lexicon Pharmaceuticals annual accounts payable?
The current annual accounts payable of LXRX is $14.39 M
What is the all time high annual accounts payable for Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals all-time high annual accounts payable is $52.88 M
What is Lexicon Pharmaceuticals annual accounts payable year-on-year change?
Over the past year, LXRX annual accounts payable has changed by +$3.99 M (+38.42%)
What is Lexicon Pharmaceuticals quarterly accounts payable?
The current quarterly accounts payable of LXRX is $14.20 M
What is the all time high quarterly accounts payable for Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals all-time high quarterly accounts payable is $66.55 M
What is Lexicon Pharmaceuticals quarterly accounts payable year-on-year change?
Over the past year, LXRX quarterly accounts payable has changed by +$2.17 M (+17.99%)